San Francisco Fed President Mary Daly said the economy is on solid footing and reinforced the central bank's ability to respond to any government initiatives.
The crisis at UnitedHealth Group Inc. (NYSE: UNH) continues to deepen, with a new criminal investigation by federal authorities, following the abrupt departure of its CEO, and a steep decline in stock prices.
The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.
Computex 2025 will spotlight Nvidia CEO Jensen Huang as he returns to headline the first major Asian tech gathering since Trump's tariff threats, with expected announcements on new AI partnerships amid rising geopolitical and industry shifts.
During the 35-day bear market, I often lamented missed gains in Options Chatyrts. Recently, my UNH $500 puts broke the trend—now worth 8x what I sold them for.
On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including a notable purchase of Airbnb Inc. (NASDAQ:ABNB), a sell-off of Palantir Technologies Inc. (NASDAQ:PLTR) ,
Senate Minority Leader Sen. Chuck Schumer (D-N.Y.) attacked President Donald Trump’s reported decision to parole family members of Mexican cartel leaders into the United States on Wednesday, implying a potential connection to the Official Trump (CRYPTO: TRUMP) meme coin.
The company completed patient dosing in its Phase 2/3 trial for IHL-42X, a once-daily oral treatment for obstructive sleep apnea. Retail enthusiasm surged as the company eyes FDA talks, Phase 3 rollout in the U.S., and early commercial interest.
GBP/USD pared recent gains on Wednesday, trimming back to the low side of the 1.3300 handle and falling back into a choppy near-term consolidation phase.
Silver price fell 2% on Wednesday amid elevated US Treasury bond yields as investors seemed confident that the US Federal Reserve would not reduce interest rates.
CEO Chuck Robbins noted momentum with AI, fueled by "the power of our secure networking portfolio, our trusted global partnerships, and the value we bring to our customers."
Jeff Bezos weathered Amazon's 94% stock crash during the dot-com bust by focusing on business fundamentals, not market panic — a strategy that helped turn the company into a $2.2 trillion giant.
UnitedHealth shares are plunging after hours following a report from The Wall Street Journal that the DOJ is investigating UnitedHealth Group for possible criminal Medicare fraud related to its Medicare Advantage business.
Income investors need to make sure they do not fall into a dividend ‘trap’, meaning purchasing a stock solely due to its high yield, only to see the company cut or eliminate the dividend payout.
With PPI on deck Thursday, traders are bracing for signs of tariff pass-through creeping into producer costs. That keeps the Fed sidelined and rate cut hopes on ice.
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full year’s revenue to be around $59.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 3.4% below analysts’ consensus estimates.
Chocolate company Hershey (NYSE:HSY) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 13.8% year on year to $2.81 billion. Its non-GAAP profit of $2.09 per share was 8.2% above analysts’ consensus estimates.
Electronic equipment provider Vontier (NYSE:VNT) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 1.9% year on year to $741.1 million. The company expects next quarter’s revenue to be around $735 million, close to analysts’ estimates. Its non-GAAP profit of $0.77 per share was 6.2% above analysts’ consensus estimates.
Industrial products distributor Applied Industrial (NYSE:AIT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.8% year on year to $1.17 billion. Its GAAP profit of $2.57 per share was 6.5% above analysts’ consensus estimates.
Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue guidance of $2 billion at the midpoint came in 6.1% below analysts’ estimates. Its non-GAAP loss of $2.22 per share was 28.6% above analysts’ consensus estimates.
